Reports from Europe and the United States have revealed that the combined application of NEGL or urine biomarkers [9], such as NGAL, KIM-1, and proteinuria, is potentially helpful for the differential diagnosis of cirrhosis-related AKI, but this should be further explored. The gene discussed is LCN2; the disease is Cirrhosis.